Skip to main content

Table 2 Trogocytosis capabilities of tumor cells from hematological malignancy patients

From: Trogocytic intercellular membrane exchanges among hematological tumors

 

Allogeneic trogocytosis

Autologous trogocytosis

 

Donor cells

Trogocytic cells (%)

Donor cells

Trogocytic cells (%)

Acceptor cells

PKH67

HLA-G1

PKH67

T lymphoma

LCL-HLA-G1

57.8

35.5

T lymphoma

55.7

B cell Lymphoma (mantle)

12.6

12.5

B cell lymphoma (mantle)

8.1

B-CLL 15

17.9

9.3

B-CLL 15

23

B-CLL 14

14.7

11.7

B-CLL 14

11.5

B-CLL 13

15

9.1

B-CLL 13

22.2

B-CLL 12

0.8

15.7

  

B-CLL 11

2.5

19.1

  

B-CLL 10

nt

23.4

  

B-CLL 9

nt

30.4

  

B-CLL 8

nt

16.7

  

B-CLL 7

nt

29

  

B-CLL 6

nt

30.1

  

B-CLL 5

nt

5

  

B-CLL 4

nt

28.5

  

B-CLL 3

nt

9.6

  

B-CLL 2

nt

7.4

  

B-CLL 1

nt

21

  
  1. Experiments were performed as described in materials and methods and as exemplified in Figure 2 for patient B-CLL 15. The individual results obtained for each indicated patient are presented. For both allogeneic and autologous trogocytosis experiments, acceptor and donor cells are indicated. The percentage of trogocytic cells is the percentage of acceptor cells that acquired PKH67 and/or HLA-G1 from PKH67hi donor cells. nt not tested.
Back to article page